Kura Oncology said its Q2 2026 financial update was accompanied by continued momentum in its clinical pipeline. The company pointed to progress in targeted ther

Kura Oncology said its Q2 2026 financial update was accompanied by continued momentum in its clinical pipeline. The company pointed to progress in targeted therapies and precision medicine, with its AML research earlier featured on the cover of Blood.